|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Capital District Health Authority, Canada |
|---|---|
| Information provided by: | Capital District Health Authority, Canada |
| ClinicalTrials.gov Identifier: | NCT00400088 |
Purpose
This study is being done to look at how well people respond to two very different drug treatments for depression. Clinically, people with depression can respond differently to drug treatments for reasons which are not always clear. Some of our own recent research suggests that people with depression who have a family history of bipolar disorder or completed suicide, may react differently to standard antidepressant medications than those without such a family history. Our data shows that family history of completed suicide, as well as the known predictor of family history of bipolar disorder, may help identify a pre-bipolar high risk group i.e. they currently have depression but at some future date will declare a bipolar illness (manic-depression) by virtue of development of a manic episode also. Our research suggests that treatment- emergent symptoms in response to a trial of antidepressant, such as agitation may be strong predictors of future bipolarity and inherently dangerous particularly as they are not ascribed to the antidepressant treatment. Finally, it is possible that this subgroup of those with depressive illness may respond better and more safely to lithium, a mood stabiliser used in known bipolar depression.
The objective of this proposal is to investigate response to acute lithium treatment in subjects who meet the diagnostic criteria for major depression, but who are potentially at risk for bipolar disorder, by virtue of family history of bipolarity or completed suicide.
| Condition | Intervention | Phase |
|---|---|---|
|
Major Depressive Disorder |
Drug: paroxetine Drug: lithium |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study |
| Estimated Enrollment: | 20 |
| Study Start Date: | June 2007 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: lithium group
Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
|
Drug: lithium
start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
Other Names:
|
|
Active Comparator: paroxetine group
Start dose at 20 mg po od. If no clinical improvement(<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
|
Drug: paroxetine
Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
Other Name: paxil
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Claire M O'Donovan, MB FRCPC | (902) 473 - 2585 | claire.odonovan@cdha.nshealth.ca |
| Contact: Julie S Garnham, BN | (902) 473 - 7144 | jgarnham@dal.ca |
| Canada, Nova Scotia | |
| Capital District Health Authority - Dept. of Psychiatry | Recruiting |
| Halifax, Nova Scotia, Canada, B3H 2E2 | |
| Contact: Julie S Garnham, BN (902) 473 7144 jgarnham@dal.ca | |
| Contact: Claire Slaney, RN (902) 473 - 5884 claire.slaney@cdha.nshealth.ca | |
| Principal Investigator: Claire M O'Donovan, MB FRCPC | |
| Principal Investigator: | Claire O'Donovan M O'Donovan, MB FRCPC | Capital District Health Authority and Dalhousie University |
More Information
| Responsible Party: | Dr Claire O'Donovan, Department of Psychiatry Dalhousie University |
| ClinicalTrials.gov Identifier: | NCT00400088 History of Changes |
| Other Study ID Numbers: | CDHA012, CDHA-RS/2006-076 |
| Study First Received: | November 15, 2006 |
| Last Updated: | June 22, 2011 |
| Health Authority: | Canada: Health Canada |
|
Major Depressive Disorder Depression Bipolar Disorder Manic Depressive Illness |
Randomized Trial Antidepressant Treatment Lithium Treatment |
|
Bipolar Disorder Depression Depressive Disorder Suicide Depressive Disorder, Major Affective Disorders, Psychotic Mood Disorders Mental Disorders Behavioral Symptoms Self-Injurious Behavior Lithium Carbonate Paroxetine Lithium Antidepressive Agents Psychotropic Drugs |
Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Antipsychotic Agents Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Serotonin Agents Antidepressive Agents, Second-Generation |